Drugs / AMG 167
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01101048 Comparator | Jun 2010 → Feb 2012 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00902356 Comparator | May → Nov 2009 | osteoporosis | Amgen | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00902356 ↗ |
| Action | Inhibit | “Sclerostin inhibitor” CHEMBL2109571 ↗ |
| Route | Subcutaneous | “700 mg SC (under the skin)” NCT00902356 ↗ |
| Target | SOST | “Sclerostin inhibitor” CHEMBL2109571 ↗ |